Dutton Associates Announces Investment Opinion: Amarillo Biosciences Speculative Buy Rating Reiterated in Update Report by Dutton Associates.EL DORADO El Dorado, legendary country of South America El Dorado (ĕl`dərä`dō, –rā`–) [Span.,=the gilded man], legendary country of the Golden Man sought by adventurers in South America. HILLS, Calif. -- Dutton Associates updates its coverage of Amarillo Biosciences, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :AMAR), maintaining its Speculative Buy rating and a 15- to 18-month price target of $1.90. The 12-page report by Dutton Associates senior analyst Wayne M. Lottenville, CFA (Computer Fraud and Abuse Act of 1986) Signed into law in 1986, the CFA was a significant step forward in criminalizing unauthorized access to computer systems and networks. The Act applies to "federal interest computers" that include any system used by the U.S. is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, and Knobias and other leading financial portals Financial Portal A website that provides a variety of financial data and information, acting as an information hub for clients who are individual investors requiring timely financial news and data to make their investment decisions. . Amarillo Biosciences is a biopharmaceutical company developing low-dose oral natural human interferon-alpha as a safe, cost-effective therapy for several diseases or their symptoms, including influenza and HIV-related oral warts. The Company has a Phase 2 clinical investigation using oral low-dose interferon-alpha for Behcet's disease Behçet's disease Behçet syndrome An idiopathic multisystem condition most common in the Middle East; ♂:♀ ratio 2:1, aged 15–40 Clinical Pustules, aphthous stomatitis–90%, genital ulcers; vasculitis; erythema nodosa–80%, now underway and plans to begin enrollment in a Phase 2 clinical trial phase 2 clinical trial Phase 2 study. See Phase study. in December to treat oral warts in HIV-positive patients. Influenza and chronic cough chronic cough, n health condition characterized by either a lingering cough or a recurring cough lasting more than a month. trials may begin in 2007. About Dutton Associates Dutton Associates is one of the largest independent investment research firms in the U.S. Its 28 senior analysts are primarily CFAs, and have expertise in many industries. Dutton Associates provides continuing analyst coverage of 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors. The current cost of enrollment in our one-year continuing research program is US $39,500 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $35,000 from the Company for 4 Research Reports with coverage commencing on 9/18/06. The Firm does not accept any equity compensation. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion